The European Medicines Agency wants to include a restriction to the indication for Veklury (remdesivir), Gilead Sciences’ COVID-19 treatment that was fast-tracked and approved conditionally in the EU a few months ago.
The agency has recommended changing the drug's indication to make it clearer in which COVID-19 patients requiring supplemental oxygen the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?